Modern Chinese Medicine Group Co Ltd

Modern Chinese Medicine Group Co Ltd exhibits a highly liquid balance sheet, with a current ratio of 8.54, indicating strong short-term liquidity. The company holds total assets of CNY 543.4 million and total liabilities of CNY 45.4 million, resulting in a debt-to-equity ratio of 0.0, suggesting no long-term debt burden. However, the risk assessment notes that net cash is negative after subtracting total debt, signaling potential liquidity constraints despite the high current ratio. Profitability metrics are weak, with a return on equity (ROE) of -2.72% and a return on assets (ROA) of -2.49%, both significantly below the industry median for pharmaceutical companies. The company reported a net loss of CNY 13.6 million and an operating loss of CNY 14.0 million in the latest period, indicating ongoing operational challenges. The company's revenue of CNY 145.2 million is derived primarily from its domestic operations, with no disclosed international revenue segments. This geographic concentration increases exposure to local regulatory and economic conditions. No material revenue is attributed to specific product lines or geographic regions beyond the disclosed domestic focus. The company's growth trajectory is uncertain, with no disclosed revenue growth or decline in the latest period. The absence of forward-looking guidance and the current operating losses suggest a lack of clear growth drivers. The risk assessment indicates low dilution potential, with no near-term pressure from share issuance or convertible debt. Recent filings and transcripts have not disclosed material events or strategic shifts. The company's 10-K filing highlights ongoing challenges in R&D commercialization and market expansion, but no specific near-term catalysts are identified.